Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill capsule, a proprietary platform technology designed to replace subcutaneous or IV injections of biologics (including antibodies, proteins, peptides, and oligonucleotides) with oral dosing. The company has advanced multiple preclinical and clinical programs evaluating safety, tolerability, and bioavailability of its delivery platform across therapeutic areas including obesity, immunology, and rare disease. In January 2026, Rani announced a collaboration with Chugai Pharmaceutical worth up to $1.085 billion alongside a concurrent $60.3 million financing.
Rani Therapeutics is publicly traded
IPO'd on July 30, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under RANI.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2012
Employees
51–200
Total Funding
$257.9M
6 rounds
Total raised $257.9M across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series E (second close)
Date
December 10, 2020
Amount
$69M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| December 10, 2020 | Series E (second close) | $69M | — | Not disclosed |
| 2020 | Series E (initial close) | $50M | — | Not disclosed |
| February 2018 | Series D Extension | $53M | — | Not disclosed |
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Lyndra Therapeutics
Clinical-stage biopharmaceutical company developing the LYNX oral drug delivery platform that converts daily medications into weekly or monthly oral dosing.
Biora Therapeutics
Develops smart-pill technologies including BioJet and NaviCap platforms that deliver medications orally to specific GI sites, positioned as alternatives to injectable biologics.
Biograil
Pre-clinical pharmaceutical company developing BIONDD oral delivery technology to convert injectable biologics into oral capsules.
Yes, Rani Therapeutics is publicly traded under the ticker symbol RANI on the NASDAQ. The company went public in July 30, 2021.
Rani Therapeutics trades under the ticker symbol RANI on the NASDAQ. It began trading in July 30, 2021.
Rani Therapeutics (RANI on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker RANI to place an order.
Rani Therapeutics went public in July 30, 2021 via ipo. Rani Therapeutics priced its IPO of 6,666,667 Class A shares at $11.00 per share on July 30, 2021, raising approximately $73.3 million in gross proceeds. Shares began trading on the Nasdaq Global Market under ticker RANI on July 30, 2021. The IPO priced below the initial $14-$16 range. In October 2025, the company announced a $60.3M concurrent financing alongside its $1.085B Chugai collaboration.
Rani Therapeutics raised $257.9M across 6 disclosed funding rounds prior to its public listing.
Rani Therapeutics was founded by Mir Imran in 2012.
Rani Therapeutics is headquartered in San Jose, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.